Menu Search
Equities

Episurf Medical AB

16E:STU

Episurf Medical AB

Actions
  • Price (EUR)0.015
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-75.97%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Episurf Medical AB had net income fall 22.77% from a loss of 77.30m to a larger loss of 94.90m despite a 53.62% increase in revenues from 6.90m to 10.60m.
Gross margin--
Net profit margin-624.22%
Operating margin-642.19%
Return on assets-66.09%
Return on equity-76.67%
Return on investment-75.45%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Episurf Medical AB fell by 97.40m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 84.90m for operations while cash used for investing totalled 9.50m.
Cash flow per share-0.1674
Price/Cash flow per share--
Book value per share0.1558
Tangible book value per share0.1032
More ▼

Balance sheet in SEKView more

Episurf Medical AB appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio6.46
Quick ratio6.17
Total debt/total equity0.0305
Total debt/total capital0.0296
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.